Drug Trial Radar · NCT05890521
Safety Study of COVID19 Vaccine on the Market
Last checked: Nov 19, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100,000
Planned (sponsor's estimate)
Start
Apr 2, 2022
Primary completion
Jun 16, 2022
Study completion Jun 2023
Sponsor
- Lead sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Hunan Provincial Center for Disease Control and Prevention; Guizhou Center for Disease Control and Prevention; Hainan Center for Disease Control & Prevention
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Popular topic:Multi-center safety observation of recombinant Novel Coronavirus protein vaccine (CHO cells) in a large population Study population:People aged 18 and above
Conditions
- COVID-19
Interventions
Recombinant new coronavirus vaccine (CHO cell)Biological
Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person. Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAETime frame: The period from receipt of the first dose of vaccine to 1 year after receipt of the last dose
- AETime frame: The period from receipt of the first dose of vaccine to 1 year after receipt of the last dose
- AESITime frame: The period from receipt of the first dose of vaccine to 1 year after receipt of the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.